{
    "ticker": "RVP",
    "name": "Reviva Pharmaceuticals, Inc.",
    "description": "Reviva Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of central nervous system (CNS) disorders and other serious diseases. Founded in 2011, Reviva's lead product candidate, RP5063, is a novel antipsychotic agent designed to treat schizophrenia and other disorders while minimizing side effects commonly associated with existing treatments. The company employs a unique approach to drug development by leveraging its proprietary technologies and extensive clinical expertise to address unmet medical needs in the CNS space. Reviva is committed to advancing its pipeline through rigorous clinical trials and partnerships, aiming to bring safe and effective therapies to patients. The company's mission is to improve the quality of life for individuals suffering from serious mental health conditions by providing innovative treatment options that optimize therapeutic outcomes.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Jose, California, USA",
    "founded": "2011",
    "website": "https://www.revivapharma.com",
    "ceo": "Laxminarayan B. Bhat",
    "social_media": {
        "twitter": "https://twitter.com/RevivaPharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals/"
    },
    "investor_relations": "https://www.revivapharma.com/investors",
    "key_executives": [
        {
            "name": "Laxminarayan B. Bhat",
            "position": "CEO"
        },
        {
            "name": "Sanjay Gupta",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Development",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals, Inc. | Innovative CNS Therapies",
        "meta_description": "Reviva Pharmaceuticals is focused on developing novel therapeutics for CNS disorders. Learn about our innovative drug candidates and commitment to patient care.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "Biopharmaceuticals",
            "Innovative Therapies",
            "RP5063"
        ]
    },
    "faq": [
        {
            "question": "What does Reviva Pharmaceuticals specialize in?",
            "answer": "Reviva Pharmaceuticals specializes in developing innovative therapeutics for central nervous system disorders."
        },
        {
            "question": "Who is the CEO of Reviva Pharmaceuticals?",
            "answer": "Laxminarayan B. Bhat is the CEO of Reviva Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Reviva Pharmaceuticals headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Jose, California, USA."
        },
        {
            "question": "What is Reviva's lead product candidate?",
            "answer": "Reviva's lead product candidate is RP5063, a novel antipsychotic agent."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2011."
        }
    ],
    "competitors": [
        "ACAD",
        "PTCT",
        "SAGE",
        "VRTX"
    ],
    "related_stocks": [
        "BIIB",
        "REGN",
        "AMGN",
        "GILD"
    ]
}